The U.S. osteoporosis drugs market is projected to generate USD 9,105.2 million by 2030, advancing at a CAGR of 4.90% during 2022–2030. Whereas, the European Union osteoporosis drugs market is predicted to reach USD 4,265.4 million by 2030, advancing at a CAGR of 4.65% during 2022–2030. This can be ascribed to the increasing healthcare expenditure, the high prevalence of osteoporosis, and the rising number of clinical trials for such drugs in the U.S. and the EU.
Based on type, the market is categorized into bisphosphonates, RANK ligand inhibitors, parathyroid hormone therapy, selective estrogen receptor modulators (SERMs), and others. Among these, the bisphosphonates category accounts for the largest revenue share. This is because such drugs are widely used to treat a variety of solid tumors affecting bones and slow down bone resorption, the rising number of osteoporosis-related fractures, and the increasing cases of bone-related chronic diseases. Additionally, such drugs can be taken orally and intravenously, which provides patients the ease to use them.
The parathyroid hormone therapy category will register significant growth during the predicted period. This can be because this therapy is used to treat hyperparathyroidism, the surging need for a synthetic form of natural human hormone injection for the treatment of such diseases, and the burgeoning number of fracture cases.
The injectable category, based on route of administration, will witness a higher growth rate in the coming years. This can be ascribed to the mounting launches and approvals of new osteoporosis injectables, enhanced patient outcomes, and patients finding such solutions handy.
Based on application, the primary osteoporosis category holds a larger revenue share and it is further expected to maintain its position during the forecast period. This is ascribed to the growing aging population and the rising number of osteoporosis cases in postmenopausal women.
The U.S. contributes a larger revenue share than the EU in the market, and it is further expected to maintain its position during the predicted period. This is ascribed to the presence of prominent industry players, the growing elderly population associated with osteoporosis disease, the surging healthcare spending, the sedentary lifestyle along with rapid urbanization, the increasing treatment strategies for osteoporosis, the rising clinical trials for such drugs, and the high availability of branded drugs.
Moreover, the EU market will register significant growth during the forecast period. This can be due to the growing healthcare infrastructure, the increasing number of healthcare product and service providers, the surging count of women in the postmenopausal stage, and the burgeoning number of hospitals and clinics in the region.
Some of the major players operating in the U.S. and European Union osteoporosis drugs market are Eli Lilly and Company, Amgen Inc., Aurobindo Pharma, Sandoz International GmbH, Organon & Co., Cipla Ltd., Polpharma API, Teva Pharmaceutical Industries Limited, Pfizer Inc., and EffRx Pharmaceuticals SA.